Vinay Prasad on Cancer Drug Prices Disconnected From Benefit: warns against

What Prasad says

Dr. Vinay Prasad warns against multi-million-dollar price tags for drugs with uncertain clinical benefit — citing Elevidys at “$3.2m” per dose as his prime example. His research also estimated that cancer patients spend 16 more hours per month on treatment access and receipt versus supportive care alone — a burden he calls “time toxicity.”

His stated reasoning

Prasad’s stated reasoning is that prices should track proven patient benefit, and that charging millions for therapies without demonstrated survival gains exploits both patients and the health system. He counts the time cost of treatment — hours spent accessing and receiving care — as part of the price patients actually pay.

This page chronicles a stated position of the person above. It is not medical advice and not the site's own conclusion.